



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/899,513	07/05/2001	Yi Hu	LEX-0200-USA	9922

24231 7590 09/09/2003

LEXICON GENETICS INCORPORATED  
8800 TECHNOLOGY FOREST PLACE  
THE WOODLANDS, TX 77381-1160

EXAMINER

LI, RUIXIANG

ART UNIT	PAPER NUMBER
1646	17

DATE MAILED: 09/09/2003

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES PATENT AND TRADEMARK OFFICE

---

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

**MAILED**  
**SEP 09 2003**  
**GROUP 2900**

**BEFORE THE BOARD OF PATENT APPEALS  
AND INTERFERENCES**

**Paper No. 17**

Application Number: 09/899, 513

Filing Date: July 5, 2001

Appellant(s): SCOVILLE ET AL.

---

David W. Hibler  
For Appellant

**EXAMINER'S ANSWER**

This is in response to the appeal brief filed 19 June 2003 (Paper No. 16).

**(1) *Real Party in Interest***

A statement identifying the real party in interest is contained in the brief.

**(2) *Related Appeals and Interferences***

A statement identifying the related appeals and interferences which will directly affect or be directly affected by or have a bearing on the decision in the pending appeal is contained in the brief.

**(3) *Status of Claims***

The statement of the status of the claims contained in the brief is correct.

**(4) *Status of Amendments After Final***

The appellant's statement of the status of amendments after final rejection contained in the brief is correct.

**(5) *Summary of Invention***

The summary of invention contained in the brief is essentially correct, except the asserted utilities for the claimed invention are currently being disputed.

**(6) *Issues***

The appellant's statement of the issues in the brief is correct.

**(7) *Grouping of Claims***

Appellant's brief includes a statement that the claims stand or fall together.

**(8) *ClaimsAppealed***

The copy of the appealed claims contained in the Appendix to the brief is correct.

**(9) *Prior Art of Record***

Ji et al., G-protein-coupled receptors, *J. Biol. Chem.* 273:17299-17302, 1998.

Peer Bork and Eugene V. Koonin, Predicting functions from protein sequences--  
where are the bottlenecks? *Nature Genetics* 18:313-318, 1998.

Yan et al., Two-amino acid molecular switch in an epithelial morphogen that  
regulates binding to two distinct receptors. *290: 523-527, 2000.*

**(10) *Grounds of Rejection***

The following ground(s) of rejection are applicable to the appealed claims:

***Claim Rejections—35 U.S.C. § 101***

Claims 5-7 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well-established utility.

Claims 5-7 are drawn to an expression vector comprising a nucleotide sequence that encodes SEQ ID NO: 2 and hybridizes to SEQ ID NO: 1, an expression vector comprising the nucleotide sequence of SEQ ID NO: 1, and a host cell comprising the expression vector. The claimed invention is not supported by either a specific and substantial asserted utility or a well-established utility. A specific and substantial utility is one that is particular to the subject matter claimed and that identifies a “real world” context of use for the claimed invention which does not require further research.

The specification asserts that the deduced amino acid sequence set forth in SEQ ID NO: 2 shares sequence similarity with mammalian membrane ligand binding

proteins (page 1, lines 8-11; page 2, 1<sup>st</sup> and 2<sup>nd</sup> paragraphs). Nonetheless, the specification fails to disclose the degree of homology with a particular membrane protein, and more importantly, fails to provide the ligand(s), biological functions, or any physiological significance of the amino acid sequence of SEQ ID NO: 2 or the nucleic acid sequence encoding SEQ ID NO: 2. Furthermore, in view of the diversity of structure and functions of the proteins, prediction of function using comparative sequence analysis may lead to the creation and propagation of assignment errors if not performed appropriately (See, Peer Bork and Eugene V. Koonin, Predicting functions from protein sequences--where are the bottlenecks? *Nature Genetics* 18:313-318,1998). There are putative seven transmembrane molecules, which do not appear to be coupled to a G protein (Ji et al. G-protein-coupled receptors, *J. Biol. Chem.*, 273:17299-17302, 1998). In certain cases, a change of two-amino acid residues in a protein results in switching the binding of the protein from one receptor to another (Yan et al, Two-amino acid molecules switch in an epithelial morphogen that regulates binding to two distinct receptors. *Science*, 290:523-527, 2000). Thus, the asserted utilities in the specification based upon the protein sequence homology are not specific and substantial.

The specification asserts that the nucleic acid sequences of the present invention are useful for identification of coding sequence and mapping a unique gene to a particular chromosome, as well as identification of the actual biologically relevant exon splice junctions (page 3, 2<sup>nd</sup> paragraph). The specification also asserts that the nucleotide sequences can be used to regulate gene expression (page 2, 3<sup>rd</sup>

paragraph; page 9, 2<sup>nd</sup> paragraph) or can be used as hybridization probes for screening libraries (page 6, 2<sup>nd</sup> paragraph; page 11, 3<sup>rd</sup> paragraph). The specification additionally asserts the use of the protein of the present invention in generation of antibodies (page 19, last paragraph). However, such uses are all considered research uses only designed to identify a particular function of the claimed molecules and are not a substantial utility. See, e.g., *Brenner v. Manson*, 383 U.S. 519, 148 USPQ 689 (Sup. Ct. 1966) wherein a research utility was not considered a "substantial utility." Moreover, such uses are not specific to the instant molecule but applicable to any nucleic acids or proteins.

The specification further asserts that the nucleic acid molecules, proteins, fusion proteins, and antibodies of the present invention "can be useful" for the detection of mutant proteins for the diagnosis of disease (page 15, 3<sup>rd</sup> paragraph), or for screening agonists, antagonist, and drugs (page 3, 3<sup>rd</sup> paragraph; page 15, 3<sup>rd</sup> paragraph). The specification asserts that the molecules of the present invention can be used as therapeutics (page 16, 2<sup>nd</sup> paragraph) to directly treat diseases or disorders (page 16, 2<sup>nd</sup> paragraph). These asserted utilities are not specific and substantial because they do not identify or reasonably confirm a "real world" context of use. The specification fails to disclose the biological functions of the protein or nucleic acids of the present invention and any diseases that are associated with or can be treated with the molecules. Clearly, further research would be required to identify a disease that is associated with the molecules or a disease that can be treated with the molecules. See *Brenner v. Manson*, 383 U.S. 519, 148 USPQ 689

(Sup. Ct. 1966), noting that "a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion."

The invention also lacks a well-established utility. A well-established utility is a specific, substantial, and creditable utility that is well known, immediately apparent, or implied by the specification's disclosure of the properties of a material. The assertion that the human protein has the sequence similarity with mammalian membrane ligand-binding proteins does not endow the claimed molecules with a specific and substantial utility. No art of record discloses or suggests any property or activity for the claimed molecules such that another non-asserted utility would be well-established for the claimed invention.

In summary, all asserted uses of the present invention are simply starting points for further research and investigation into potential practical uses of the claimed nucleic acids. "Congress intended that no patent be granted on a chemical compound whose sole 'utility' consists of its potential role as an object of use-testing."

*Brenner v. Manson*, 148 USPQ at 696.

#### ***Claim Rejections—35 U.S.C. § 112, First Paragraph***

Claims 5-7 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

#### ***(11) Response to Argument***

**A. Do claims 5-7 lack a Patentable Utility?**

Beginning at the bottom of page 3 of the Brief, Appellant argues that a sequence that has over 99% identity at the protein level with the claimed sequence is present in GenBank (Accession No. AX647175, Exhibit A), and has been annotated by third party scientists wholly unaffiliated with Appellant as "G-protein coupled receptor". Appellant urges that given this GenBank annotations, there can be no question that those skilled in the art would clearly believe that the Appellant's sequence is a G-protein coupled receptor.

Appellant's arguments have been fully considered but are not deemed to be persuasive for the following reasons. First, the Examiner notes that the key issue at dispute is not a matter of whether the present nucleic acids encode a membrane protein or a putative GPCR; rather, it is a matter of whether the present nucleic acids encode a GPCR with defined ligands and biological functions; it is a matter of whether the present nucleic acid sequences have a patentable utility. The answers to these questions are "No" (see reasons detailed below).

Secondly, the specification merely asserts that the amino acid sequence of SEQ ID NO: 2 shares sequence similarity with mammalian membrane proteins, and fails to explicitly state the amino acid sequence of SEQ ID NO: 2 is a GPCR. Appellant only started using the term "GPCR" in the argument in response to the First Office in Paper No. 9. Nowhere does the specification disclose the ligand(s), biological functions, or any physiological significance of the putative membrane protein encoded by the present nucleic acid sequences; nowhere does the specification disclose any evidence

supporting the assertion that the amino acid sequence of SEQ ID NO: 2 is a truly functional GPCR and is involved in signal transduction pathway; nowhere does the specification disclose that the amino acid sequence of SEQ ID NO: 2 shares sequence homology with a particular G-protein coupled receptor, as annotated for the sequence published in GenBank (Accession No. AX647175, Exhibit A). In other words, Appellant did not contemplate that the amino acid sequence of SEQ ID NO: 2 was specifically related to the G-protein coupled receptor of AX647175.

Thirdly, the sequence homology of the predicted amino acid sequence of SEQ ID NO: 2 with the GPCR sequence published in GenBank (Accession No. AX647175, Exhibit A) is insufficient to justify the functions of the amino acid sequence of SEQ ID NO: 2 or its encoding nucleic acid sequences and thus is insufficient to provide the claimed invention a patentable utility. The Examiner points out that the GenBank annotation, which corresponds to European patent Application EP 1270724, does not provide a specific and substantial utility for the amino acid sequence of SEQ ID NO: 2, its encoding nucleic acid sequence, and the present invention because the GPCR of GenBank (Accession No. AX647175, Exhibit A) is also an "orphan receptor" whose ligand(s) and biological functions remain to be identified.

Most importantly, the art teaches that it is impossible to predict precisely the functions of protein molecules solely base upon sequence analysis, in view of the diversity of structure and functions of GPCRs (Bork and Eugene V. Koonin, *Nature Genetics* 18:313-318,1998). There were nearly 2000 GPCRs up to 1998 and they are classified into over 100 subfamilies according to sequence homology, ligand structure,

and receptor function. There are putative seven transmembrane molecules, which do not appear to be coupled to a G protein (Ji et al., *J. Biol. Chem.* 273:17299-17302, 1998; see beginning of the article). A variety of studies have shown that minor differences in sequence can account for different binding affinities and activities. For example, a change of two-amino acid residues in a protein results in switching the binding of the protein from one receptor to another (Yan et al., *Science* 290: 523-527, 2000).

Furthermore, there is no single well-established utility for the GPCR family due to the great diversity in structures and functions of the GPCR family. The ligands and biological functions or any physiological significance of a GPCR requires specific determination. Thus, even the sequence analysis can classify a GPCR into the GPCR family; such an assignment does not render a specific biological function and thus a well-established utility to the GPCR, as is the case here.

Finally, it is noted that the instant application was filed 5 July 2001. No evidence has been brought forth during the prosecution history regarding the ligand(s) and biological activities of the proteins encoded by the present nucleic acid sequences. It clearly weighs in favor of the Examiner's position that the functions of the amino acid sequence of SEQ ID NO: 2 and its encoding nucleic acids remain elusive.

Beginning at the second paragraph of page 4 of the Brief, Appellant criticizes the rejection's use of Bork and Koonin (*Nature Genetics* 18:313-318, 1998), Ji et al. (*J. Biol. Chem.* 273:17299-17302, 1998), and Yan et al. (*Science* 290:523-527, 2000). Appellant

argues that these articles fail to support the lack of utility of the presently claimed sequence.

Appellant urges that the Bork and Koonin article is hardly indicative of a high level of uncertainty in assigning function based on sequence. This has been fully considered but is not deemed to be persuasive because it ignores the overall teachings of Bork and Koonin article. Bork and Koonin's remarks clearly indicate that the potential importance of sequence analysis in extracting functional signal. However, Bork and Koonin do not teach, in any means, that sequence analysis alone can define the biological functions. In fact, Bork and Koonin clearly teach that the exponential growth of sequence data does not necessarily lead to an increase in knowledge about the functions of genes and their products and that prediction of function using comparative sequence analysis may lead to the creation and propagation of assignment errors if not performed appropriately (Abstract). Bork and Koonin further teach that many proteins are multifunctional, assignment of a single function, which is still common in genome projects, results in loss of information and outright errors (Table 2). As stated at page 4 of Paper No. 12, while sequence analysis is important, the information provided or "predicted" based upon sequence homology can only be used as guidance in determining functions or activities of a molecule by experiments. Any functions predicted based upon the sequence homology will have to be confirmed ultimately by direct experimentation.

Appellant urges that an exact quote from Ji et al. completely undermines the question of asserted utility based upon protein homology: "a substantial degree of

amino acid homology is found between members of a particular subfamily, but comparisons between subfamilies show significantly less or no similarity". Appellant further urges that homology with members of a G-protein coupled receptor is indicative that the particular sequence is in fact a member of that subfamily. This has been fully considered but is not deemed to be persuasive for the following reasons. First, the Examiner notes that the critical issue at dispute is not a matter of whether the present nucleic acids encode GPCRs; rather, it is a matter of whether the GPCRs encoded by present nucleic acids have defined biological functions and have a patentable utility. The cited statement simply indicates that a substancial degree of amino acid homology is found among members of a particular subfamily. However, two sequences sharing certain degree homology do not necessarily have the same functions. Secondly, the specification merely asserts that the amino acid sequence set forth in SEQ ID NO: 2 shares sequence similarity with mammalian membrane ligand binding proteins (page 1, lines 8-11; page 2, 1<sup>st</sup> and 2<sup>nd</sup> paragraphs). Nowhere in the specification specifies a functional G-protein coupled receptor with which the protein encoded by the present nucleic acid sequences share sequence homology and the degree of homology. Finally, Ji et al. clearly teach there are putative seven transmembrane molecules, which do not appear to be coupled to a G protein (page 17299, third paragraph of left column, Ji et al.). Even if the proteins encoded by the present nucleic acid sequences were able to be placed, based upon sequence homology, in the GPCR family, there would still not a patentable utility for the claimed invention because there is no common use and thus there is no well established utility for the diversified GPCR family. In this regard, it is

noted that there are nearly 2000 G-protein coupled receptors up to 1998, and there are over 100 subfamilies classified according to the sequence homology, ligand structure and receptor functions (beginning of the article of Ji et al.).

Appellant argues that the paper of Yan et al. cites only one example, two isoforms of the anhidrotic ectodermal dysplasia (EDA) gene, where a two amino acid change conforms one isoform (EDA-A1) into the second isoform (EDA-A2) and does not suggest a high level of uncertainty in assigning function based on sequence, and thus does not support the lack of utility. Specifically, Appellant argues that the different receptors bound by the two isoforms of ectodysplasin are related and that EDA-A2 receptor was correctly identified as a member of the tumor necrosis factor receptor superfamily based upon solely on sequence similarity.

This has been fully considered but is not deemed to be persuasive for the following reasons. First, the paper of Yan et al., while citing only one example, clearly demonstrates that the unpredictability of the functions of proteins solely based upon sequence homology. While the two receptors bound by the two isoforms of ectodysplasin are related, i.e., belonging to the TNFR superfamily, they clearly have different activities (See, e.g., page 524, column 3) and are distinct receptors. Even the title of the paper clearly states that the two receptors bound by the two isoforms are distinct. Secondly, while the EDA-A2 receptor was initially identified as a member of the TNFR superfamily solely based on sequence similarity, as applicants argued, the biological functions of the receptor were not identified. In fact, Yan et al. performed undue experimentation as described in the paper to define the ligand and biological

activities of the EDA-A2 receptor. As taught by Yan et al., members of the TNFR superfamily are involved in a number of physiological and pathological response by activating a wide variety of intracellular signaling pathways (beginning of page 523). The EDA-A2 receptor (XEDAR) fails to bind many known ligands of the TNFsuperfamily (1<sup>st</sup> column of page 524). Therefore, even if sequence analysis could assign a given protein to a protein family, the protein does not necessarily possess the same functions of a member of the family. Consequently, the protein does not have a substantial utility because the biological function or activity is not defined and determining such a biological function of the protein would require significant further research, as demonstrated by Yan et al., which is not allowed under 35 U.S.C. § 101. As is the case here.

At second paragraph of page 5 of the Brief, Appellant criticizes the PTO for denying the utility of nucleic acid sequence of the present invention by citing the journal articles and argues that the legal test for utility simply involves an assessment of whether those skilled in the art would find any of the utilities described for the invention to be believable and that the overwhelming majority of those skilled in the art would believe bioinformatic prediction to be powerful and useful tool and would thus believe that the present sequence is a GPCR.

Appellant's arguments have been fully considered but are not deemed to be persuasive for the following reasons. First, as noted above, the specification merely asserts that the amino acid sequence of SEQ ID NO: 2 shares sequence similarity with

mammalian membrane proteins, and fails to explicitly state the amino acid sequence of SEQ ID NO: 2 is a GPCR. Appellant only started using the term "GPCR" in the argument in response to the First Office in Paper No. 9. Secondly, the key issue at dispute is not a matter of whether the present nucleic acids encode a membrane protein or a putative GPCR; rather, it is a matter of whether the present nucleic acids encode a GPCR with defined ligands and biological functions; it is a matter of whether the present nucleic acid sequences have a patentable utility. Since the specification fails to disclose the biological functions or any physiological significance, the claimed invention lacks a specific and substantial utility.

Beginning at the bottom of page 5 of the Brief, Appellant argues that as 60% of the pharmaceutical products currently being marked by the entire industry target G-protein coupled receptors, a preponderance of the evidence clearly weighs in favor of Appellant's assertion that the skilled artisan would readily recognize that the presently described sequences have a specific, credible, and well-established utility, for example in tracking gene expression, particularly using a gene chip. Appellant further argues that such "DNA chips" clearly have utility, as evidenced by hundreds of issued U.S. Patents and industrial success.

This has been fully considered but is not deemed to be persuasive for the following reasons. First, commercial success is not an indication of patentability and the commercial value does not simply render the claimed invention a specific, substantial, and credible utility. This is because many products may be commercially successful due

Art Unit: 1646

to reasons unrelated to the use of the products such as fads or clever commercial advertising. For example, a pharmaceutical company may wish to purchase a putative GPCR on the chance that it may turn out to be a drug target in the future, even though determining such possibility requires substantial further experimentation. However, such substantial further experiment is not acceptable for patentable utility. In addition, substantial further experiment may have already been done on some of the GPCRs mentioned by Appellant in the Brief and specific functions may have already been known. This is not the case here.

Secondly, the Examiner would like to draw the Board's attention to the definition of the terms "a gene chip" and "a micro array" mentioned in the Brief and in the instant specification by the Appellant. A gene chip is a customized device in biomedicine that allows researchers to detect, simultaneously, the presence and activity patterns of tens of thousands of DNA sequences in pieces of genetic material. A micro array can be used by researchers to describe the genetic malfunction associated with a disease, detect the presence of the disease in a particular patient, calculate a patient's genetic predisposition to that disease or identify the medicines likely to be most effective in treating a particular patient with the disease.

The instant specification has not established that the nucleic acid sequences of the present invention are expressed at altered levels or forms in a specific diseased tissue as compared with the corresponding healthy tissue. If the nucleic acid molecules of the present invention were in a microarray and a compound caused decreased expression of the nucleic acids, what would that mean to the skilled artisan? Is it a

potential drug, or would administering the compound be likely to exacerbate an unspecified disease? If it had been disclosed that the nucleic acids of the present invention are expressed at a higher level in a particular diseased tissue as compared with the corresponding healthy tissue, the skilled artisan would know that a compound that decreased expression of the nucleic acid molecules is a good drug candidate that targets the disease. It is not the case here.

In addition, a nucleic acid molecule may very well be expressed at equivalent levels in healthy and diseased tissues. If that were the case, the compound would not be a good drug candidate. A nucleic acid molecule may also very well be expressed at a lower level in a particular diseased tissue as compared to the corresponding healthy tissue. Then a compound that decreased expression of the polynucleotide would *not* be a good potential drug. Evidence of a differential expression might serve as a basis for use of a nucleic acid molecule as a diagnostic for a disease. However, in the absence of any disclosed relationship between a nucleic acid molecule (or protein encoded by the nucleic acid) and any diseases or disorders, any information obtained from an expression profile would only serve as the basis for further research on the observation itself. "Congress intended that no patent be granted on a chemical compound whose sole 'utility' consists of its potential role as an object of use-testing." *Brenner v. Manson*, 148 USPQ at 696. Thus, the specification does not present a substantial utility that would support the requirement of 35 U.S.C. §101.

Finally, the issued U.S. Patents related to DNA chips merely show that the technology itself is important and useful; they do not show that claimed invention has a

patentable utility. There is no doubt that a gene chip (or DNA chips) is a valuable tool in gene expression monitoring and drug discovery. However, the claims are not drawn to the technique, rather to expression vectors comprising nucleic acid molecules which have not been disclosed as being associated with any particular diseases or conditions by its being expressed at an altered level or form in a specific diseased tissue as compared to the corresponding healthy tissue. Any such nucleic acid molecules could be added to a micro array. The use of the uncharacterized nucleic acid molecules of the present invention in such studies would have provided no more valuable information than the use of any other unidentified nucleic acids. Thus, this asserted utility is not specific. Determining the relationship between the nucleic acid molecules and any specific diseases or disorders would require significant further research. Therefore, this asserted utility is also not substantial.

Beginning at the bottom of page 6 of the Brief, Appellant criticizes the statement "Since the disclosure does not reveal any activity/function of the nucleotide sequence or the protein encoded by the nucleotide sequence, one skilled in the art would not know how to use the claimed invention" and argues that expression profiling does not require a knowledge of the function of the particular nucleic acid on the chip—rather the gene chip indicates which fragments are expressed at greater or less levels in two or more particular tissue types.

This has been fully considered but is not deemed to be persuasive for the following reasons. First, Appellant is mischaracterizing the Examiner's position. A

specification can meet the legal requirements of utility and enablement for a nucleic acid as long as the specification discloses a specific and substantial asserted utility or a well-established utility for the nucleic acid. A hypothetical example may serve to clarify. For example, a hypothetical specification discloses that a nucleic acid is expressed in colon cancer and not expressed in healthy colon tissue. The hypothetical specification does not disclose the biological activity of the polypeptide encoded by the nucleic acid. The claimed nucleic acid in the hypothetical example would not be rejected under 35 U.S.C. §§ 101 and 112, first paragraph, as it has a specific and substantial and is enabled as a colon cancer marker.

However, it is not the case here. The instant specification merely asserts that the amino acid sequence of SEQ ID NO: 2 shares sequence similarity with mammalian membrane ligand binding proteins (page 1, lines 8-11; page 2, 1<sup>st</sup> and 2<sup>nd</sup> paragraphs). There is no disclosure that the nucleic acid encoding SEQ ID NO: 2 is expressed at altered levels or forms in any specific, diseased tissue. It is noted that the instant application was filed 5 July 2001. No evidence has been brought forth during the prosecution history regarding the expression levels in diseased or healthy tissue; no evidence has been brought forth on the biological activities of the proteins encoded by the present nucleic acids. Since the specification fails to discloses nucleic acid molecules as being associated with any particular diseases or conditions by its being expressed at an altered level or form in a specific diseased tissue as compared to the corresponding healthy tissue, as discussed above, what meaningful results could one possibly obtain even one can carry out the assay using a gene chip?

Furthermore, if Appellant intends to argue that the present nucleic acid sequences can be used in a gene chip to determine their differential expression associated with a certain disease, it is analogous to argue that the claimed nucleic acid sequences lack a patentable utility in its current available form and establishment of the usefulness requires further significant research.

At the 2<sup>nd</sup> paragraph of page 7 of the Brief, Appellant argues that persons skilled in the art, as well as venture capitalists and investors, readily recognize the utility, both scientific and commercial, of human genomic data and that the usefulness of the claimed nucleic acid molecules is substantial and credible and well established. This has been fully considered but is not deemed to be persuasive because while human genomic data have both scientific and commercial value, neither the commercial success related to human genomic project nor the publications cited by the Appellant shows a patentable utility for the presently claimed nucleic acid sequences.

Beginning at the middle of page 7 of the Brief, Appellant submits that a specific utility should not be confused with the requirement for a unique utility. Appellant argues, citing a case law, that the fact that other expressed sequences can be used to track gene expression on a DNA chip does not mean that the use of Appellants' sequence to track gene expression on a gene chip is not a specific utility.

Appellant's arguments have been fully considered but are not deemed to be persuasive for the following reasons. First, Appellant is mischaracterizing the

examiner's position regarding the requirements of a specific utility and a unique utility. There is no dispute on the case law itself. The issue at dispute is what constitutes a specific utility. A specific utility is a utility specific to the subject matter claimed. This contrasts with a general utility that would be applicable to the broad class of the invention. To satisfy the utility requirement under 35 U.S.C. § 101, a utility does not need to be unique; however, it must be specific. For example, a claim drawn to a polynucleotide whose use is disclosed simply as "a gene probe" or "chromosome marker" would not be considered to be specific in the absence of disclosure of a specific DNA target; a general statement of diagnostic utility, such as diagnosing an unspecified disease, would ordinarily be insufficient absent a disclosure of what condition can be diagnosed. Likewise, the asserted use of the present nucleic acid sequence to track gene expression on a gene chip is not considered a specific utility in the absence of disclosure of any physiological significance of the nucleic acid sequence. Any human nucleic acids can be used on a gene chip.

It is further noted that the patents on batteries, automobile tires, golf balls, and treatments for a variety of human diseases are issued by the USPTO because the invention in each patent has a specific and substantial utility, not simply because the claimed subject matter is related to batteries, automobile tires, golf balls, or disease treatment. For example, a golf ball has a specific feature that makes the ball fly higher and further away as compared with other golf balls; a compound has a particular property that can be used to treat a specific disease, e.g., prostate cancer. It is not the case here.

Beginning at the middle of page 8 of the Brief, Appellant argues that the present polynucleotide sequences have a specific utility in mapping the sequences to a specific region of a human chromosome and provide biologically validated empirical data that specifically define that portion of the corresponding genomic locus that actually encodes exon sequence. This has been fully considered but is not deemed to be persuasive because such a utility is considered a research utility only designed to identify a particular function of the claimed sequences and is not a substantial utility. See, e.g., *Brenner v. Manson*, 383 U.S. 519, 148 USPQ 689 (Sup. Ct. 1966) wherein a research utility was not considered a "substantial utility." Moreover, such a utility is not specific to the instant molecule, rather applicable to any polynucleotide sequences encoding proteins. While the Examiner agrees with the Appellant on the scientific value of the claimed polynucleotide sequences and on the significance of expressed sequence information in structural analysis of genomic data, such a use of the polynucleotide sequences in gene mapping does not represent a specific and substantial utility. The exhibit and the publication cited by the Appellant merely show that the significance of expressed sequences in the structural analysis of genomic data; they do not show that the present polynucleotide sequence has a patentable utility.

At the middle of page 9, Appellant, citing case law, argues that a statement of utility in a specification must be accepted absent reasons why skilled in the art would have reason to doubt the objective truth of such statement. This has been fully

considered but is not deemed to be persuasive because the first Office Action of Paper No. 9 and Final Rejection of Paper No. 12 have clearly set forth the reasons why the claimed invention lacks a specific and substantial utility or a well-established utility.

Beginning at the bottom of page 9 of the Brief, Appellant summarizes case law on the utility requirement. Citing case law, Appellant urges that the present claims clearly meet the requirement of 35 U.S.C. §101. Appellant further argues that FDA approval is not a prerequisite for finding a compound useful within the meaning of the patent laws.

Appellant's argument has been fully considered but is not deemed to be persuasive for the following reasons. First, the essential disagreement appears to be the interpretation of what constitutes a specific, substantial and credible utility, and on the statement "(t)o violate §101 the claimed device must be totally incapable of achieving a useful result." *Brooktree Corp. v. Advanced Micro Devices, Inc.*, 977 F.2d 1555, 1571, 24 USPQ2d 1401 (Fed. Cir. 1992). The statement quoted from the device case law indicates that a rejection under 35 U.S.C. § 101 *for lack of operability* can be overcome by a showing of actual use or commercial success. The claimed invention in the instant case is drawn to an isolated nucleic acid expression vector comprising a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 2 and a host cell comprising the expression vector, not a device; the instant rejection under 35U.S.C. §101 is not directed to inoperativeness of a device, rather to a lack of patentable utility

of the claimed invention; and the instant issue is whether the asserted utilities meet the three-pronged test for a patentable utility.

Secondly, since the specification fails to disclose a specific, substantial utility or a well-established utility, the present claims do not satisfy the utility requirement of 35 U.S.C. §101. Merely citing case laws on the utility requirement does not render a patentable utility for the present invention. While “anything under the sun that is made by man” is patentable, it does not necessarily mean the present invention is patentable. In fact, the present invention is not patentable due to lack of a patentable utility.

Furthermore, while the FDA approval is not a prerequisite for finding a compound useful within the meaning of the patent laws, and the requirement for the utility of the claimed invention is different from the FDA standard for drug approval, 35 U.S.C. §101 does require a specific, substantial, and credible utility, or well-established utility for an invention. Such a utility has to be a “real world “ context of use which does not require significant further research. Appellant confuses this requirement with the “further research and development” needed in pharmaceutical composition and drug development. In other words, a patentable utility has to be clearly identified or immediately apparent in the specification, whereas some “further research and development” is permitted in drug development. For example, determining optimal dosages or drug tolerance in human is further research and development, which is acceptable under 35 USC 101 because it is not significant. On the other hand, determining a specific disease to be treated by a drug constitutes significant further research and development, which is not acceptable under 35 U.S.C. §101.

Art Unit: 1646

In the instant case, the specification merely discloses that the deduced amino acid sequence of SEQ ID NO: 2 shares sequence similarity with mammalian membrane ligand binding proteins (page 1, lines 8-11; page 2, 1<sup>st</sup> and 2<sup>nd</sup> paragraphs), but fails to disclose the biological functions or any physiological significance of the amino acid sequence of SEQ ID NO: 2 or the nucleic acid sequence encoding SEQ ID NO: 2. It would require undue experimentation to determine the biological functions or any physiological significance of the sequences of the present invention. See *Brenner v. Manson*, 383 U.S. 519, 148 USPQ 689 (Sup. Ct. 1966), noting that "a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion."

It is further noted that the instant application was filed 5 July 2001. No evidence on the biological functions or physiological significance of the sequences of the present invention has ever been brought forth in an appropriate form during the prosecution history. It weighs clearly in favor of Examiner's position that significant further research or undue experimentation is required to identify such information.

Finally, beginning at bottom of page 11 of the Brief, Appellant challenges the legality of the Patent Examination Utility Guidelines and the validity of issued US patents. It is noted that an Examiner has no authority to comment on the legality of the Guidelines and the validity of US Patents.

Appellant concludes this section by urging that the rejection of claims 5-7 under 35 U.S.C. § 101 must be overruled. The Examiner believes that the rejections should be sustained for the reasons set forth above.

**B. Are Claims 5-7 Unusable Due to a lack of Patentable Utility?**

As Appellant indicates at page 13 of the Brief, a rejection under § 112, first paragraph, may be affirmed on the same basis as a lack of utility rejection under § 101.

Therefore, for reasons set forth above, Appellant's arguments and exhibits have been fully and carefully considered, but are not considered sufficient to rebut the prima facie case of lack of utility.

For the above reasons, it is believed that the rejections should be sustained.

Respectfully submitted,

Ruixiang Li, Ph.D.  
September 2, 2003

Conferees  
Yvonne Eyer, Ph.D.  
SPE, Art Unit 1646

*Yvonne Eyer*  
YVONNE EYLER, PH.D  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600

Anthony Caputa, Ph.D.  
SPE, Art Unit 1642

*A*  
ANTHONY C. CAPUTA  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600